1. Home
  2. AIN vs DNTH Comparison

AIN vs DNTH Comparison

Compare AIN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$54.04

Market Cap

1.7B

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$78.51

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
DNTH
Founded
1895
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
AIN
DNTH
Price
$54.04
$78.51
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$60.25
$121.90
AVG Volume (30 Days)
291.7K
1.1M
Earning Date
06-01-2026
06-01-2026
Dividend Yield
2.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,054,132,000.00
$2,036,000.00
Revenue This Year
$2.89
N/A
Revenue Next Year
N/A
$58.85
P/E Ratio
N/A
N/A
Revenue Growth
7.29
N/A
52 Week Low
$41.15
$13.37
52 Week High
$75.16
$88.45

Technical Indicators

Market Signals
Indicator
AIN
DNTH
Relative Strength Index (RSI) 38.90 70.18
Support Level $52.23 $34.83
Resistance Level $60.43 N/A
Average True Range (ATR) 2.02 4.87
MACD -0.61 2.04
Stochastic Oscillator 18.88 72.63

Price Performance

Historical Comparison
AIN
DNTH

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: